Arthrosi to Present Positive Phase 2 Data for its Novel Selective URAT1 Inhibitor AR882 in Patients with Tophaceous Gout at ACR Convergence 2023
Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for gout that dissolve uric
Arthrosi Announces Multiple Presentations at the American College of Rheumatology (ACR) Convergence 2023
Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company developing treatments to reduce uric acid levels
Arthrosi Therapeutics AR882 Prepares to Enter into Global Phase 3 Study
Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, has announced they have received written response
About Us
Arthrosi Therapeutics is a clinical-stage biotech company focused on the development of therapy for gout and chronic kidney disease. Its proprietary drug candidate, AR882, demonstrated unprecedent sustained urate lowering in gout patients and showed potential to treat a variety of renal impaired patients suffering from gout and tophaceous gout..
Arthrosi strives to…
- Create a people-centered environment — you are at the center of everything we do and every decision we make.
- Be your partner in health — we work to bring a better quality of life to our patients.
US gout patients
with flares
with tophi
chronic refractory gout patients
A large percentage of the 9 million patients living with gout are undertreated, relying on short-term or sub-optimal treatments that don’t meet their needs. Our mission is to eliminate the pain of gout with a new era of gout treatment that provides a true solution to reduce flare and tophi.
Litain Yeh
Co-Founder and CEO
